Category: ACMPR

David Hyde on recent upgrades to ACMPR licensing process

In our most recent conversation with David Hyde, we discuss the changes to Health Canada’s medical cannabis licensing program announced last May and their impacts on the licensing process for both applicants and producers seeking to build new production space. The changes to Health Canada’s regulations—announced last May when they released a backgrounder entitled Improving the Licensing of

Health Canada says no medical cannabis shortages, patients disagree

Product shortages continue to frustrate many medical cannabis consumers, despite claims from Health Canada that there is a sufficient supply to meet patient demands. As interest in Canada’s medical cannabis program continues to increase, concerns with supply have also been increasing. In January of this year, Lift first tackled the issue of product shortages, showing that

Health Canada rushes to correct lack of pesticide testing for cannabis

New testing limits for pesticides are causing some frustration for producers and labs who say these limits are being set retroactively, reflecting poorly on an industry with a reputation for otherwise robust regulations. In the wake of pesticide-related recalls from OrganiGram and Mettrum late last year and early this year, Health Canada recently announced new surprise

Over 4,000 now able to grow medical cannabis

Enrolment in Health Canada’s personal cultivation program has nearly doubled in less than three months, according to new figures from the agency. To handle this, Health Canada’s Office of Medical cannabis recently hired 17 new employees to help with processing and responding to questions. As of May 1, there are now 4,480 Canadians with active

Health Canada updates pesticide testing requirements in wake of new results

Today Health Canada announced the results of a new inspection and testing program in the wake of several pesticide-related recalls in the last six months. The regulator also announced that it will now require all licensed producers to conduct mandatory testing of all cannabis products destined for sale for the presence of unauthorized pesticides. Preliminary results

Peace Naturals to begin selling clones

Ontario’s Peace Naturals has added cannabis clones to its available products for registered patients. It is the sixth company now to offer clones for sale after Health Canada changed the rules to allow the sale of ‘starting materials’ from licensed cannabis producers to registered patients. Peace Naturals will be initially offering one strain for sale,

Hydropothecary issues voluntary stopsale for unauthorized fungicide

The Hydropothecary Corporation today announced a voluntary stop­-sale and stop­-shipment on all products due to detection of myclobutanil, a fungicide not approved for use on cannabis in Canada. The company emphasizes this is not a recall of product, as the fungicide was found on plants, not finished cannabis products. The company says the source of

Canada’s medical marijuana program growing by more than 10,000 a month

Health Canada reports that as of January 31, 2017, there were nearly 142,541 clients registered with licensed producers of medical cannabis. This figure is up from 130,000 as of December 31 of last year. At the end of June, 2015, there were almost 24,000 registered patients, increasing exponentially each quarter. As more Canadians become aware

Office of Medical Cannabis seeks to enhance how regulations enforced, interpreted

Canada’s Office of Medical Cannabis (OMC) is seeking to work with producers to help streamline their medical cannabis regulations, according to an announcement sent out to licensed producers under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). In keeping with Health Canada’s Regulatory Transparency and Openness Framework (RTOF), introduced in 2014 with the goal of presenting

Health Canada issues recall for mislabelled THC level

Health Canada announced today that on March 8, 2017, Aphria, a licensed producer of cannabis for medical purposes located in Ontario, began a voluntary recall of one lot of dried marijuana under a Type III recall. One lot (652-4883) of cannabis was mislabelled as containing 22.3% THC instead of 21.1% THC. A Type III recall refers